Nikki Church

Nikki Church

Auto-generated profile, based on publicly available information

Nikki Church

Bayer, Whippany, New Jersey

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2018 in Haemophilia
Verified
Journal Article
Open access
PDF file
NCN. Church
N. Church
LLL. Leong
L. Leong
YKY. Katterle
Y. Katterle
HUH.‐F. Ulbrich
H.‐F. Ulbrich
INI. Noerenberg
I. Noerenberg
LML. A. Michaels
L. A. Michaels
Introduction: Discrepancies in the measurement of modified factor VIII (FVIII) products have been recognized, highlighting the need for adjustments in clinical laboratory practices to ensure effective monitoring of patients treated with these products, particularly using the one‐stage (activated partial thromboplastin time [aPTT]) assay.Aim: To assess the ability of clinical laboratories to measure the activity of BAY 94‐9027, a PEGylated extended half‐life FVIII product, using routine (predominantly one‐stage) assays in clinical laboratoriesMethods: Blinded samples of FVIII‐deficient plasma spiked with defined levels of BAY 94‐9027 and a recombinant FVIII product comparator were provided to 52 clinical laboratories that routinely conduct FVIII testing. Samples were provided at 3 concentrations (low, medium and high), and laboratories analysed the samples using routine in‐house one‐stage and, when available, chromogenic assays. Acceptable spiked recovery (accuracy) of the local laboratory methods to measure BAY 94‐9027 was the primary endpoint of the study.Results: Accurate FVIII measurements were obtained at all concentrations for both products using the chromogenic assay and most of the commonly used one‐stage reagents, both ellagic acid and silica based. Two specific silica‐based reagents, APTT‐SP and PTT‐A, underestimated BAY 94‐9027 levels at all concentrations, consistent with previous findings.Conclusions: FVIII activity of BAY 94‐9027 was accurately measured with most commonly used one‐stage assays used in routine clinical practice. The chromogenic assay was also accurate. It is recommended that clinical laboratories identify and avoid specific inappropriate reagents, such as the APTT‐SP and PTT‐A, in their one‐stage assays for FVIII monitoring.

1 July 2016 in Journal of Blood Medicine
Verified
Journal Article
Open access
PDF file
NLNanxin Li
Nanxin Li
JPJennifer Pocoski
Jennifer Pocoski
RARajeev Ayyagari
Rajeev Ayyagari
NCNikki Church
Nikki Church
MEMonika Maas Enriquez
Monika Maas Enriquez
JXJipan Xie
Jipan Xie
Background: No head-to-head trials comparing recombinant factor VIII (rFVIII) products currently exist. This was a matching-adjusted indirect comparison (MAIC) study of efficacy of BAY 81-8973 with antihemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM) and turoctocog alfa for the prophylaxis of severe hemophilia A. Methods: A systematic literature review was conducted to identify trials of rAHF-PFM and turoctocog alfa. Comparisons were conducted using BAY 81-8973 individual patient data (IPD) from LEOPOLD trials and published data from rAHF-PFM and turoctocog alfa trials. Differences in outcome reporting were reconciled using transformation of BAY 81-8973 IPD. Patients in pooled LEOPOLD trials were weighted to match baseline characteristics for rAHF-PFM or turoctocog alfa trials using MAICs. After matching, annualized bleed rates (ABRs) were compared using weighted t-tests. Results: Two rAHF-PFM trials and one turoctocog alfa trial were identified. In these trials, rFVIIIs were dosed thrice weekly or every other day; in LEOPOLD trials, BAY 81-8973 was dosed twice- or thrice weekly. Three MAICs were conducted because the two rAHF-PFM trials calculated ABRs differently, matching for age, race, and weight (turoctocog alfa only). BAY 81-8973 had similar ABR of all bleeds vs rAHF-PFM (two trials: 4.8 vs 6.3, 1.9 vs 1.8 [square root transform]) and lower ABR of spontaneous bleeds and trauma bleeds (2.6 vs 4.1, 2.1 vs 4.7; both P<0.05). BAY 81-8973 showed lower ABR of all bleeds and spontaneous bleeds vs turoctocog alfa (4.3 vs 6.5, 2.8 vs 4.3; both P<0.05) and similar ABR of trauma bleeds (1.5 vs 1.6). In subgroup analysis, twice-weekly BAY 81-8973 had similar ABRs of all bleeds, spontaneous bleeds, and trauma bleeds compared to rAHF-PFM and turoctocog alfa.
Conclusion:
This indirect comparison found that prophylaxis with BAY 81-8973, even including the lower frequency of two times a week and lower factor VIII consumption, has efficacy comparable to rAHF-PFM and turoctocog alfa, which were dosed thrice weekly or every other day. The use of IPD enabled adjustments for differences in calculation of ABRs and population characteristics between trials.

17 April 2019 in Haemophilia
Verified
Journal Article
Open access
PDF file
RYRenchi Yang
Renchi Yang
JSJing Sun
Jing Sun
YZYongqiang Zhao
Yongqiang Zhao
XWXuefeng Wang
Xuefeng Wang
DWDepei Wu
Depei Wu
NCNikki Church
Nikki Church
Introduction: BAY 81‐8973 (Kovaltry®) is a full‐length, unmodified recombinant human factor VIII approved in China for prophylaxis and on‐demand treatment in patients with haemophilia A. Limited access to FVIII prophylaxis in China has historically led to this population being undertreated. This subanalysis of LEOPOLD II investigated whether the efficacy and safety of BAY 81‐8973 varied between Chinese and non‐Chinese patients.Aim: To evaluate BAY 81‐8973 efficacy and safety in Chinese patients.Methods: LEOPOLD II enrolled males aged 12‒65 years with severe haemophilia A who were receiving on‐demand treatment. Patients were randomly assigned to receive BAY 81‐8973 as low‐dose prophylaxis (20‒30 IU/kg twice‐weekly), high‐dose prophylaxis (30‒40 IU/kg 3 times weekly) or on‐demand for 1 year.Results: Data were available from 23 Chinese and 57 non‐Chinese patients; Chinese patients had a higher prestudy bleeding rate and were more likely to have target joints than non‐Chinese patients. 74% of patients were assigned to prophylaxis. Annualized bleeding rates (ABRs) in Chinese and non‐Chinese patients receiving prophylaxis were significantly lower compared to patients treated on‐demand. Median ABRs for all bleeds in the last 6 months of the study were 2.0 and 1.0 for Chinese and non‐Chinese patients, respectively, in the combined prophylaxis groups, and 61.3 and 58.5 in the on‐demand group. A treatment‐related adverse event occurred in 1 Chinese patient; no patients developed FVIII inhibitors.Conclusion: BAY 81‐8973 prophylaxis was efficacious and well tolerated in Chinese patients with severe haemophilia A, with ABRs comparable to those in non‐Chinese patients receiving prophylaxis.

26 September 2019 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
SFSharon M. Funk
Sharon M. Funk
SESylvia Engelen
Sylvia Engelen
KBKaty Benjamin
Katy Benjamin
OMOlga Moshkovich
Olga Moshkovich
BGBrittany Gentile
Brittany Gentile
MMMarilyn J. Manco‐Johnson
Marilyn J. Manco‐Johnson
Background The Colorado Adult Joint Assessment Scale (CAJAS) is designed to assess joint health in adults with hemophilia. The CAJAS comprises nine items (Swelling, Muscle Atrophy, Axial Deformity, Crepitus, Range of Motion, Contracture, Instability, Strength, Gait) and assesses six joints. Objective To assess CAJAS content validity and psychometric properties. Patients/Methods Data were obtained from the SPINART study and a separate CAJAS validation study. CAJAS assessments in SPINART were performed by physical therapists (PTs) from the United States, Romania, Bulgaria, and Argentina. In the validation study, content validity was assessed from interviews with six PTs at three US hemophilia centers; cultural equivalence was assessed with seven non‐US PTs from SPINART. Reliability data were collected from 30 subjects at four US centers. Test‐retest reliability was evaluated by having the same PT perform CAJAS examinations at two visits, seven to ten days apart. Inter‐rater reliability was assessed by comparing CAJAS scores of two different PTs performing separate examinations of the same patient several hours apart at the same visit. Psychometric properties were assessed using SPINART and validation study data. Results The CAJAS demonstrated good content validity. Test‐retest reliability was high (intraclass correlation coefficient [ICC], 0.98), as was inter‐rater reliability (ICC, 0.88). Internal consistency reliability was strong (α = 0.90). The CAJAS demonstrated good convergent/divergent validity, known‐groups validity, and ability to detect change. Conclusions The CAJAS is a valid and reliable measure of joint health in adults with moderate‐severe hemophilia and is appropriate for use in clinical practice.

12 June 2018 in Therapeutic Advances in Hematology
Verified
Journal Article
Open access
PDF file
JMJohnny Ndoni Mahlangu
Johnny Ndoni Mahlangu
SASanjay P. Ahuja
Sanjay P. Ahuja
JWJerzy Windyga
Jerzy Windyga
NCNikki Church
Nikki Church
ASAnita Shah
Anita Shah
LSLawrence Schwartz
Lawrence Schwartz
BAY 81-8973 (Kovaltry®) is an unmodified, full-length recombinant factor VIII (rFVIII) approved for the prevention and treatment of bleeding episodes in patients with hemophilia A. The amino acid sequence for BAY 81-8973 is identical to that of sucrose-formulated rFVIII (rFVIII-FS; Kogenate® FS/KOGENATE®, Bayer), but the two products differ in their manufacturing approaches. The manufacture of BAY 81-8973 includes several modifications and enhancements, such as the introduction of the gene for human heat shock protein 70, a molecular chaperone protein that facilitates folding of proteins; no addition of human- or animal-derived proteins in the cell culture, purification process, or final formulation; and use of a 20-nm filter to remove any potential aggregates and pathogens. BAY 81-8973 was extensively studied in the LEOPOLD clinical development program, which enrolled participants of all age groups (children, adolescents, and adults) with severe hemophilia A. The pharmacokinetic profile of BAY 81-8973 was shown to be noninferior to, and for some variables more favorable than, rFVIII-FS and another commercial full-length rFVIII product. BAY 81-8973 was shown to be efficacious when used for prophylaxis, on-demand treatment, and perioperative hemostasis. The efficacious prophylaxis dose of BAY 81-8973 was approximately 20–40 IU/kg given two or three times per week, which achieved low annualized bleeding rates. Either the one-stage or the chromogenic assay provides accurate measurements for postinfusion monitoring of BAY 81-8973 levels, with no product-specific calibration standard needed. The incidence of treatment-related adverse events was ⩽7% across all LEOPOLD studies, and no previously treated patient developed anti-BAY 81-8973 inhibitors in the completed primary studies.